Charles River Associates’ global Life Sciences practice offers diverse skills, relevant insights and extensive experience in Life Sciences policy, business strategy, finance and economics consulting. CRA focuses on delivering high quality, robust analysis but in a compelling fashion that is accessible to the target audience. CRA’s policy team provides analysis and insights into issues affecting the life sciences industry including international and national trade associations (through EFPIA, PhRMA, and IFPMA) and individual companies. CRA also commonly works for the European Commission and national governments and has a reputation for independence and rigour.
Denoon Legal is a specialist life science law firm based in London. In addition to a broad experience of advising pharmaceutical and medical technology companies, it has particular expertise in the regulation of regenerative medicine, stem cells and other advanced therapies and embryo research. Denoon Legal is generally involved in these fast-changing areas before the law is on the statute book, whether in Brussels or in London.
Leela Barham is a Health Economist by training with an MSc Health Economics from the University of York and BSc Economics from the University of Nottingham. Leela has over a decade of experience in consulting, working with clients from across the world.
Leela focuses on policy and health economic issues from the pharmaceutical pricing to Health Technology Assessment and more. Leela has worked with patient organisations, the NHS, a health insurer, think tanks, the pharmaceutical industry and the medical device industry.
Leela has also worked for the Royal College of Nursing and NERA Economic Consulting and been a member of the Department of Health's External Advisory Group on Payment by Results and the HFMAs Costing Special Interest Group.
Leela's work has been published in a number of journals and she also regularly contributes to pharmaceutical industry magazines. She has also been a peer reviewer for journals including the European Journal of Health Economics and The Patient.
Mr. Anthony Barron is a senior associate in the Life Sciences Practice of Charles River Associates. He is a health economist with more than nine years of experience focused on European and global healthcare policies. Anthony has a strong understanding of health financing and pharmaceutical market access issues and has conducted a number of research projects on industrial policy in the pharmaceutical sector in Europe. This includes a report commissioned by EFPIA, on the impact of Brexit on the life sciences industry where he examined the positive and negative impact that a change in the UK relationship with the EU might have upon activities along the industry’s value chain.
Julian Hitchcock is Counsel at the boutique life science practice, Denoon Legal (part of the Alliance of European Life Science Law Firms), based in London. He specialises in the law and regulation of emerging life science technologies, including regenerative and reproductive technologies, genetic and mitochondrial manipulation and synthetic biology. He provides policy, regulatory and intellectual property advice to commercial, clinical, academic, charitable, regulatory and governmental institutions. Julian is a former director of the East of England Stem Cell Network, associate of the PHG Foundation and member of the UK government's Emerging Science and Bioethics Advisory Committee. He is currently a member of the governance subgroup of the UK’s Synthetic Biology Leadership Council, a member of the Nuffield Council on Bioethics’ genome editing working party, a trustee of the UK Science Media Centre and an associate of the Innogen Institute.